• Childhood Kidney Diseases
• /
• 제1권1호
• /
• pp.91-96
• /
• 1997

Polycystic kidney disease is defined as a heritable disorder with diffuse involvement of both kidneys without dysplasia other than cysts. The major clinical entities of autosomal recessive polycystic kidney disease and autosomal dominant polycystic kidney disease have a considerable overlap in clinical presentations and radiographic features in the pediatric population. We experienced three cases of autosomal recessive polycystic kidney disease of neonate who expired within 24 hours due to respiratory difficulty and the other case was detected by gross hematuria. So we report four cases with brief review of literatures.

• Childhood Kidney Diseases
• /
• 제22권2호
• /
• pp.64-66
• /
• 2018

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease and causes terminal chronic renal failure. ADPKD is characterized by bilateral multiple renal cysts, which are produced by mutations of the PKD1 and PKD2 genes. PKD1 is located on chromosome 16 and encodes a protein that is involved in cell cycle regulation and intracellular calcium transport in epithelial cells and is responsible for 85% of ADPKD cases. Although nine cases of unilateral ADPKD with contralateral kidney agenesis have been reported, there have been no reports of early childhood ADPKD. Here, we report the only case of unilateral ADPKD with contralateral kidney dysplasia in the world in a four year-old girl who was intrauterinely diagnosed since she was 20 weeks old and followed for four years until present.

• Childhood Kidney Diseases
• /
• 제27권2호
• /
• pp.76-81
• /
• 2023

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD. Tolvaptan has already been used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.

• Childhood Kidney Diseases
• /
• 제1권2호
• /
• pp.144-150
• /
• 1997

목적 : 낭포성 신질환은 다양한 임상증상, 조직학적 소견 및 예후를 나타내는 질환군이다. 이 질환은 종류에 따라 임상 증상이 발현되는 시기나 나타나는 신질환의 정도가 다르다. 유전성 또는 발달장애가 원인인 낭포신이 있고, 소아에서는 드물지만, 성인에서는 후천성으로 생기는 낭포신이 있다. 다양한 원인에도 불구하고 낭포형성의 과정은 비슷한 것으로 알려져 있다. 최근들어 영상진단의 발달로 본 질환의 조기 진단이 가능해졌으나 아직 그 치료는 만족스럽지 못하다. 본 연구에서는 낭포성 신질환의 분포, 빈도, 동반기형, 발견동기, 치료 및 예후에 대해서 알아보고자 한다. 방법 : 1986년 1월부터 1996년 12월까지 11년간 18세 미만의 낭포성 신질환 환아 44명을 대상으로 임상 기록지를 토대로 후향적 고찰을 시행하였다. 결과 : 1) 낭포성 신질환 환아 44명중 다발성 낭포성 이형성 신(multicystic dysplastic kidney)이 31명(71%)으로 가장 많았고, 다낭포 신(polycystic kidney)이 7명(16%)이었으며 이들 모두 상염색체 열성 유전 다낭포신(Autosomal recessive polycystic kidney disease)이었다. 단순 신낭포(simple cyst)는 5명(11%)이었으며 수질성 해면신 (medullary sponge kidney)이 1명 있었다. 2) 다발성 낭포성 이형성 신 환아 31명중 11명(35%)이 암종과의 감별 및 복부 팽만 등의 이유로 신절제술을 시행받았다. 3) 전체 낭포성 신질환 환아중 14명(32%)이 신생아 시기에 발견되어 진단만 받았을뿐 더이상 검사나 추적관찰을 하지 않았다. 4) 전 예에서 신부전의 증거는 없었다. 결론 : 본 연구결과 낭포성 신질환의 정확한 발생빈도는 알 수 없었으나 그 발생 기전과 분류 및 치료기준에 대한 지속적인 연구가 필요하다고 사료된다.ed cord 증후군에서 비뇨기계의 증상 및 비정상 검사 소견이 동반되는 경우가 흔하며 비뇨기계의 이상을 시사하는 증상이 없는 경우에도 검사상 이상이 발견되는 경우가 적지 않다. Tethered cord 증후군 환아의 평가는 신경학적 이상 유무는 물론이고 비뇨기계의 이상 여부에 대한 평가도 필히 포함되어야 할 것으로 생각된다.X> 섭취량은 배추의 경우 3.72배, 양배추의 경우 4.18배, 양상추의 경우 6.50배나 많았다. 6. 결론적으로 같은 량의 엽채류를 섭식하면서 일일 질산염 섭취량을 줄이기 위해서는 배추, 양배추, 양상추 모두 외부엽보다는 내부엽을 선택적으로 소비하는 것이 바람직함을 알 수 l있었다.었다. 6. 녹즙 종류별 ${NO_3}^-$ 함량은 당근녹즙(143ppm) < 명일엽(506ppm) < 돌미나리(669ppm) < 케일녹즙(985ppm) 순으로 많았고, Vitamin C 함량은 당근(43ppm) < 돌미나리(289ppm) < 케일(353ppm) < 명일엽(768ppm)의 순으로 높았다. 7. 일일 ${NO_3}^-$ 섭취량은 500ml의 녹즙을 마시는 경우 명일엽 253mg, 돌미나리 335mg, 케일 483mg으로 녹즙만으로도 이미 WHO/FAO의 일일 ${NO_3}^-$ 섭취허용량보다 1.16배, 1.53배, 2.21배나 초과할 수 있는 것으로 나타났다. 연약한 곤충의 방제에 효과적인 것으로 나타났다. 따라서 제조된 살충비누를 활용하면 환경친화적인 해충방제가 가능하다고 판단되었다.소변의 이상소견이 발견되어 신장 조직검사를 실시할 경우 혈청 $C_3$치의 감소 여부에 관계없이 MPGN도 진단적 고려 대상이 되어야 한다고 생각한다.신장 조직검사를 시행한 결과 진행성 경과를 취할 수 있는 막 증식성 사구체 신염과 매우 희귀한 증례인 신유전분증 등으로

• BMB Reports
• /
• 제46권7호
• /
• pp.338-345
• /
• 2013

microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by targeting the 3'-untranslated region of multiple target genes. Pathogenesis results from defects in several gene sets; therefore, disease progression could be prevented using miRNAs targeting multiple genes. Moreover, recent studies suggest that miRNAs reflect the stage of the specific disease, such as carcinogenesis. Cystic diseases, including polycystic kidney disease, polycystic liver disease, pancreatic cystic disease, and ovarian cystic disease, have common processes of cyst formation in the specific organ. Specifically, epithelial cells initiate abnormal cell proliferation and apoptosis as a result of alterations to key genes. Cysts are caused by fluid accumulation in the lumen. However, the molecular mechanisms underlying cyst formation and progression remain unclear. This review aims to introduce the key miRNAs related to cyst formation, and we suggest that miRNAs could be useful biomarkers and potential therapeutic targets in several cystic diseases.

• Childhood Kidney Diseases
• /
• 제5권2호
• /
• pp.225-230
• /
• 2001

저자들은 우연히 발견된 두통성 복부 종물을 주소로 내원한 1년 4개월된 여아에서 신적출술을 시행하여 다방성 낭포성 신종을 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

• Childhood Kidney Diseases
• /
• 제3권2호
• /
• pp.221-226
• /
• 1999

Glomerulocystic kidney disease(GCKD) is a rare form of renal cystic disease defined histopathologically by containing dilated Bowman's space with variable atrophy of glomerular tufts, which may occur as sporadically or as familial cases and can be presented as a major component of heritable syndromes. It has not been recognized in Korean children but only one report of adult case has been reported having GCKD. We experienced a case of GCKD in a 10-year-10-month-old boy, who was admitted for hypertension. Abdominal ultrasonography and computed tomography revealed clustered numerous small cysts in left kidney and renal biopsy findings was consistent with the GCKD showing cystic dilatation of Bowman's space with intact glomerular structure.

• Childhood Kidney Diseases
• /
• 제21권1호
• /
• pp.1-7
• /
• 2017

Mitogen-activated protein kinases (MAPKs) play important roles in various cellular functions including proliferation, differentiation, and apoptosis. We showed that MAPKs are developmentally regulated in the rat kidney. p38 MAPK (p38) and extracellular signal-regulated kinase (ERK) were strongly expressed in the fetal kidney, whereas c-Jun N-terminal kinase (JNK) was detected predominantly in the adult kidney. The inhibition of p38 or ERK in organ culture resulted in reduced nephron formation with or without reduced kidney size. On the other hand, persistent fetal expression pattern of MAPKs, i.e., upregulation of p38 and ERK and downregulation of JNK, was observed in the cyst epithelium of human renal dysplasia, ovine fetal obstructive uropathy, and pcy mice, a model of polycystic kidney disease. Furthermore, activated p38 and ERK induced by cyclic stretch mediated proliferation and $TGF-{\beta}1$ expression in ureteric bud cells, probably leading to cyst formation and dysplastic changes. Inhibition of ERK slowed the disease progression in pcy mice. Finally, ERK and p38 were inactivated in the early embryonic kidney subjected to maternal nutrient restriction, characterized by reduced ureteric branching and nephron number. Thus, MAPKs mediate the development of normal and diseased kidney. Their modulation may result in novel therapeutic strategies against developmental abnormalities of the kidney.

• Childhood Kidney Diseases
• /
• 제28권2호
• /
• pp.51-58
• /
• 2024

Patients with chronic kidney disease (CKD) bear a significant financial burden and face numerous complications and higher mortality rates. The progression of CKD is associated with glomerular injury caused by glomerular hyperfiltration and oxidative stress. Factors such as uncontrolled hypertension, elevated urine protein levels, anemia, and underlying glomerular disease, contribute to CKD progression. In addition to conservative treatment, several medications are available to combat the progression of CKD to end-stage kidney disease. Renin-angiotensin-aldosterone system blockers could slow the progression of CKD by reducing glomerular hyperfiltration, lowering blood pressure, and decreasing inflammation. Mineralocorticoid receptor antagonists inhibit the mineralocorticoid receptor signaling pathway, thereby attenuating inflammation and fibrosis. Sodium-glucose cotransporter 2 inhibitors exhibit protective effects on the kidneys and against cardiovascular events. Tolvaptan, a selective vasopressin V2-receptor antagonist, decelerates the rate of increase in total kidney volume and deterioration of kidney function in patients with rapidly progressive autosomal dominant polycystic kidney disease. The protective effects of AST-120 remain controversial. Due to a lack of evidence regarding the efficacy and safety of these medications in children, it is imperative to weigh the benefits and adverse effects carefully. Further research is essential to establish the efficacy and safety profiles in pediatric populations.

• Biomolecules & Therapeutics
• /
• 제29권3호
• /
• pp.311-320
• /
• 2021

Accumulation of reactive oxygen species (ROS) is associated with the development of various diseases. However, the molecular mechanisms underlying oxidative stress that lead to such diseases like autosomal dominant polycystic kidney disease (ADPKD) remain unclear. Here, we observed that oxidative stress markers were increased in Pkd1f/f:HoxB7-Cre mice. Forkhead transcription factors of the O class (FOXOs) are known key regulators of the oxidative stress response, which have been observed with the expression of FoxO3a in an ADPKD mouse model in the present study. An integrated analysis of two datasets for differentially expressed miRNA, such as miRNA sequencing analysis of Pkd1 conditional knockout mice and microarray analysis of samples from ADPKD patients, showed that miR-132-3p was a key regulator of FOXO3a in ADPKD. miR-132-3p was significantly upregulated in ADPKD which directly targeted FOXO3 in both mouse and human cell lines. Interestingly, the mitochondrial gene Gatm was downregulated in ADPKD which led to a decreased inhibition of Foxo3. Overexpression of miR-132-3p coupled with knockdown of Foxo3 and Gatm increased ROS and accelerated cyst formation in 3D culture. This study reveals a novel mechanism involving miR-132-3p, Foxo3, and Gatm that is associated with the oxidative stress that occurs during cystogenesis in ADPKD.